Literature DB >> 17825262

The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Sharon R Grady1, Outi Salminen, Duncan C Laverty, Paul Whiteaker, J Michael McIntosh, Allan C Collins, Michael J Marks.   

Abstract

This review summarizes studies that attempted to determine the subtypes of nicotinic acetylcholine receptors (nAChR) expressed in the dopaminergic nerve terminals in the mouse. A variety of experimental approaches has been necessary to reach current knowledge of these subtypes, including in situ hybridization, agonist and antagonist binding, function measured by neurotransmitter release from synaptosomal preparations, and immunoprecipitation by selective antibodies. Early developments that facilitated this effort include the radioactive labeling of selective binding agents, such as [(125)I]-alpha-bungarotoxin and [(3)H]-nicotine, advances in cloning the subunits, and expression and evaluation of function of combinations of subunits in Xenopus oocytes. The discovery of epibatidine and alpha-conotoxin MII (alpha-CtxMII), and the development of nAChR subunit null mutant mice have been invaluable in determining which nAChR subunits are important for expression and function in mice, as well as allowing validation of the specificity of subunit specific antibodies. These approaches have identified five nAChR subtypes of nAChR that are expressed on dopaminergic nerve terminals. Three of these contain the alpha6 subunit (alpha4alpha6beta2beta3, alpha6beta2beta3, alpha6beta2) and bind alpha-CtxMII with high affinity. One of these three subtypes (alpha4alpha6beta2beta3) also has the highest sensitivity to nicotine of any native nAChR that has been studied, to date. The two subtypes that do not have high affinity for alpha-CtxMII (alpha4beta2, alpha4alpha5beta2) are somewhat more numerous than the alpha6* subtypes, but do bind nicotine with high affinity. Given that our first studies detected readily measured differences in sensitivity to agonists and antagonists among these five nAChR subtypes, it seems likely that subtype selective compounds could be developed that would allow therapeutic manipulation of diverse nAChRs that have been implicated in a number of human conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825262      PMCID: PMC2735219          DOI: 10.1016/j.bcp.2007.07.032

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  119 in total

1.  Pharmacological comparison of transient and persistent [3H]dopamine release from mouse striatal synaptosomes and response to chronic L-nicotine treatment.

Authors:  S R Grady; E U Grun; M J Marks; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

Review 2.  Sensitization of the mesoaccumbens dopamine response to nicotine.

Authors:  D J Balfour; M E Benwell; C E Birrell; R J Kelly; M Al-Aloul
Journal:  Pharmacol Biochem Behav       Date:  1998-04       Impact factor: 3.533

3.  Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus.

Authors:  S E File; P J Kenny; A M Ouagazzal
Journal:  Behav Neurosci       Date:  1998-12       Impact factor: 1.912

4.  Four pharmacologically distinct subtypes of alpha4beta2 nicotinic acetylcholine receptor expressed in Xenopus laevis oocytes.

Authors:  R Zwart; H P Vijverberg
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

5.  Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain.

Authors:  N Le Novère; M Zoli; J P Changeux
Journal:  Eur J Neurosci       Date:  1996-11       Impact factor: 3.386

Review 6.  Presynaptic nicotinic ACh receptors.

Authors:  S Wonnacott
Journal:  Trends Neurosci       Date:  1997-02       Impact factor: 13.837

7.  Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit.

Authors:  M J Marks; P Whiteaker; J Calcaterra; J A Stitzel; A E Bullock; S R Grady; M R Picciotto; J P Changeux; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

8.  Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats.

Authors:  D L Marshall; P H Redfern; S Wonnacott
Journal:  J Neurochem       Date:  1997-04       Impact factor: 5.372

9.  Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes.

Authors:  Y Lu; S Grady; M J Marks; M Picciotto; J P Changeux; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1998-11       Impact factor: 4.030

10.  Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.

Authors:  M J Parker; A Beck; C W Luetje
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

View more
  132 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences.

Authors:  N R Hoft; J A Stitzel; K E Hutchison; M A Ehringer
Journal:  Genes Brain Behav       Date:  2010-11-04       Impact factor: 3.449

3.  α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2010-08-23       Impact factor: 4.436

Review 4.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

5.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

6.  Partial agonists for α4β2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects.

Authors:  Ying Chen; Lisa M Broad; Keith G Phillips; Ruud Zwart
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 7.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

8.  A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction.

Authors:  L Elliot Hong; Colin A Hodgkinson; Yihong Yang; Hemalatha Sampath; Thomas J Ross; Brittany Buchholz; Betty Jo Salmeron; Vibhuti Srivastava; Gunvant K Thaker; David Goldman; Elliot A Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

9.  Prior nicotine self-administration attenuates subsequent dopaminergic deficits of methamphetamine in rats: role of nicotinic acetylcholine receptors.

Authors:  Michelle G Baladi; Shannon M Nielsen; J Michael McIntosh; Glen R Hanson; Annette E Fleckenstein
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

Review 10.  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.

Authors:  Ruthie E Wittenberg; Shannon L Wolfman; Mariella De Biasi; John A Dani
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.